1. Pink Sheet

US FDA Neuroscience Office Director Billy Dunn Departs As Agency Faces New Review Challenges

 
• By Sue Sutter

Dunn is retiring after an 18-year career that included involvement in some high-profile and controversial drug approval decisions, not the least of which is Biogen’s Alzheimer’s treatment Aduhelm; deputy director Teresa Buracchio takes over the neurology office on an acting basis.

Door handle
FDA's Billy Dunn is closing the door on an 18-year career at the agency. • Source: Shutterstock

Billy Dunn, the US FDA’s Office of Neuroscience director who spearheaded the controversial accelerated approval of Biogen, Inc.’s Alzheimer’s disease treatment Aduhelm (aducanumab-avwa) and championed the need for regulatory flexibility in rare neurodegenerative diseases, is leaving the agency.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership